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on the day of admission (OR 3.585, p = 0.049) and 24–72 h 
after admission (OR 11.515, p = 0.003) were, amongst oth-
er variables, associated with an increased 30-day mortality. 
In conclusion, only new-onset incident AF during the first 
72 h after admission was associated with 30-day mortality 
in STEMI patients.
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Introduction
Atrial fibrillation (AF) is common in the setting of ST-eleva-
tion myocardial infarction (STEMI) [1–4] and is associated 
with an increased re-infarction rate, cardiogenic shock and 
pulmonary oedema [5]. AF is also an independent predictor 
of both short-[6, 7] and long-term mortality [5, 7–12]. How-
ever, there are only limited data on the temporal association 
between new-onset AF and short-term mortality. The pres-
ent study was aimed at assessing the impact of different AF 
episode timings on 30-day mortality in patients who under-
went primary percutaneous coronary intervention (PPCI) in 
the setting of STEMI.
Methods
Our population consisted of patients with a STEMI, who were 
admitted for PPCI and included in the ongoing tirofiban in 
myocardial infarction evaluation (On-TIME) II study [13, 14], 
a prospective, multicentre, placebo-controlled, randomised, 
clinical trial. The rationale, design and primary results of 
On-TIME II have been previously described [13]. Briefly, 
enrolment was from June 2006 to November 2007. Eligible 
Abstract Atrial fibrillation (AF) is associated with short-
term mortality after ST-elevation myocardial infarction 
(STEMI), but there is limited data on the temporal asso-
ciation between AF and mortality after STEMI. A total of 
830 patients were included (age: 62 ± 12 years, 76 % male). 
Patients with new-onset AF < 30 days after STEMI were 
divided among three subgroups: AF on the day of admis-
sion, AF 24–72 h and AF > 72 h after admission. Thirty-
day mortality was assessed by telephone and via the mu-
nicipal population registry. Twenty patients died < 30 days 
after admission. In 41 patients, AF was detected on the day 
of admission, in 14 patients 24–72 h after admission and 
in 18 patients > 72 h after admission. Mortality was higher 
in patients with AF on the day of admission (7.3 vs 2.2 %, 
p = 0.036) and 24–72 h after admission (14.3 vs 1.4 %, 
p < 0.001), but not in patients with AF > 72 h after admis-
sion (0 vs 1.1 %, p > 0.999). Age (odds ratio (OR) 1.123, 
p < 0.001), Killip class (adjusted OR 8.341, p < 0.001), AF 
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patients were aged 21–85 years with symptoms of acute myo-
cardial infarction of more than 30 min but less than 24 h and 
ST-segment elevation of more than 1 mV in two adjacent elec-
trocardiograph (ECG) leads. Exclusion criteria were severe 
renal dysfunction (glomerular filtration rate < 30 ml/min or 
serum creatinine > 200 mmol/l (> 2.5 mg/dl)), therapy resis-
tant cardiogenic shock (systolic blood pressure ≤ 80 mmHg 
for > 30 min), persistent severe hypertension (systolic pres-
sure > 180 mmHg or diastolic pressure > 110 mmHg), or a 
contraindication to anticoagulation or increased risk of bleed-
ing. Also, patients with a left bundle branch block, pregnant 
and/or breastfeeding women, and patients with a life expec-
tancy of less than 1 year were excluded. For the present study, 
patients with a known history of AF were excluded. From 
each patient, written informed consent for participation in the 
On-TIME II study was obtained. The local ethics committees 
approved the study protocol.
Treatment
All patients were planned to undergo PPCI and were treated 
according to the On-TIME II study protocol, randomly 
assigned to (prehospital) treatment with tirofiban (25 μg/kg 
bolus and 0.15 μg/kg/min maintenance infusion for 18 h) or 
placebo. PPCI was performed with standard techniques, if 
the coronary anatomy was suitable for angioplasty. Addi-
tional treatment with stents and devices was at the discre-
tion of the treating cardiologist. All patients were treated 
with optimal drug therapy including angiotensin-converting 
enzyme inhibitors, β-blockers, aspirin and a statin. Final 
discharge and admission duration was at the discretion of 
the treating cardiologist.
Endpoints
The primary endpoint of the On-TIME II trial was the extent 
of residual ST-segment deviation at 1 h after PCI. For the 
present study, all-cause mortality was the primary endpoint 
of this study. To assess mortality, all patients visited the 
outpatient clinic 30 days after admission. When patients 
did not visit the outpatient clinic, an attempt was made to 
contact the patient and general practitioner to determine 
whether the patient was still alive. Furthermore, the munici-
pal population registries, which keep records of all deaths 
in participating countries, were checked in all patients > 30 
days after the STEMI. The occurrence of AF was defined 
as an episode of AF/atrial flutter/atrial tachycardia > 30 s, 
either on a telemetry strip or on a 12-lead ECG, in accor-
dance with European guidelines [15] within 30 days after 
admission. Patients were on telemetry during the first 48 h 
after admission, and an ECG was performed once every 
24 h, or whenever deemed necessary. Whenever a patient 
experienced symptoms and was not on telemetry, an ECG 
was performed immediately.
Statistical analysis
Continuous variables were expressed as mean with stan-
dard deviation (SD). Patients in whom AF was detected 
< 24 h after admission were categorised to the ‘AF on the 
day of admission’ subgroup. Patients in whom AF was 
detected 24–72 h after admission were categorised to the 
‘AF 24–72 h after admission’ subgroup. Patients in whom 
AF was detected > 72 h but < 30 days after admission were 
categorised to the ‘AF > 72 h after admission’ subgroup, 
as displayed in Fig. 1. Baseline characteristics between 
30-day mortality yes and no groups were compared with a 
Mann–Whitney U test in case of continuous variables and 
chi-square test in case of dichotomous or categorical data, 
except for data with > 20 % cells with a value < 5, in which 
case a Fisher’s exact test was used. A univariate analysis 
was performed for the association between patient charac-
teristics, biomarkers, AF and mortality with a binary logistic 
regression model. A multivariate model was not created due 
to the limited number of endpoints in this study. However, 
for each AF episode timing, we performed a multivariate 
analysis with the Zwolle risk score [16]. The Zwolle risk 
score is a composite score of 6 clinical variables: Killip 
class, TIMI flow post-PPCI, age, 3-vessel disease, anterior 
Fig. 1 Flow chart of patient categorisation into AF subgroups and 




Neth Heart J (2015) 23:430–435
tirofiban study medication (OR 0.254, p = 0.015) and TIMI 
grade post PPCI < 3 (OR 7.444, p < 0.001) were associated 
with 30-day mortality. AF on the day of admission was also 
significantly associated with 30-day mortality (OR 3.585, 
p = 0.049). In multivariate analysis, AF on the day of admis-
sion was not associated with short-term mortality (adjusted 
OR 3.537, p = 0.116). The analysis is displayed in Table 2.
Atrial fibrillation 24–72 h after admission
Mortality in patients in whom AF was detected 24–72 h 
after admission was significantly higher compared with 
patients who were AF-free (14.3 vs 1.4 %, p < 0.001), as 
displayed in Table 1. In univariate analysis, age (OR 1.111, 
p < 0.001), diabetes (OR 5.911, p = 0.001), Killip class > 1 
(OR 7.275, p < 0.001), previous myocardial infarction (OR 
4.300, p = 0.015), systolic (OR 0.708, p = 0.005) and dia-
stolic blood pressure on admission (OR 0.611, p = 0.009), 
tirofiban study medication (OR 0.254, P = 0.035), culprit 
vessel (OR 4.317, p = 0.026), TIMI grade flow < 3 post PPCI 
(OR 4.061, p = 0.019) and AF 24–72 h after admission (OR 
11.515, p = 0.003) were significantly associated with 30-day 
mortality. In multivariate analysis, AF 24–72 h after admis-
sion was independently associated with 30-day post-infarc-
tion mortality (adjusted OR 13.476, p = 0.006). The analysis 
is displayed in Table 3.
Atrial fibrillation > 72 h after admission
Mortality in patients in whom AF was detected > 72 h after 
admission did not differ among patients with AF compared 
with those without AF (0 vs 1.1 %, p > 0.999), as displayed 
in Table 1. In univariate analysis, age (OR 1.106, p = 0.002), 
diabetes (OR 6.333, p = 0.002), Killip class > 1 (OR 5.939, 
p = 0.003), previous myocardial infarction (OR 5.913, 
p = 0.005), culprit vessel (OR 5.298, p = 0.034) and TIMI 
grade flow < 3 post PPCI (OR 5.583, p = 0.006) were sig-
nificantly associated with 30-day post-infarction mortality. 
infarction and ischaemia time, and allows identification of 
STEMI patients at high risk of 30-day mortality. The differ-
ence between patient age in smoking versus non-smoking 
patients was assessed with a Mann–Whitney U test. Statisti-
cal analysis was performed using IBM SPSS statistics ver-
sion 20 (IBM inc., Armonk, NY, USA). A p-value of ≤ 0.05 
was considered statistically significant.
Results
A total of 984 patients were admitted with the diagnosis of 
STEMI. Of these patients, 861 underwent PPCI. Baseline 
characteristics of the whole study population have been pre-
viously reported [14]. A total of 31 patients had a history of 
AF and were subsequently excluded; 30-day follow-up was 
present in 830 patients, who were included in the analysis 
for the current study. Baseline characteristics of the study 
population are displayed in supplemental Table 1.
Mortality and baseline characteristics
A total of 20 patients died < 30 days after STEMI, 5 patients 
died < 24 h after admission, 3 patients died 24–72 h after 
admission and 12 patients died > 72 h after admission. AF 
was detected in a total of 73 patients: in 41 patients on the 
day of admission, in 14 patients 24–72 h after admission 
and in 18 patients > 72 h after admission, as displayed in 
Fig. 1. Patients who died were significantly older (74.2 vs 
61.8 years, p < 0.001), less often smokers (21.1 vs 49.3 %, 
p = 0.015), with more often a history of diabetes (35.0 
vs 10.1 %, p < 0.001) and hypertension (55.0 vs 32.7 %, 
p = 0.037), more often a Killip class > 1 (50.0 vs 10.7 %, 
p < 0.001), more often a previous infarction (25.0 vs 
7.8 %, p = 0.006), a lower systolic (109.1 vs 131.4 mmHg, 
p < 0.001) and diastolic blood pressure on admission (63.3 
vs 76.9 mmHg, p = 0.001), received the tirofiban study med-
ication less often (20.0 vs 49.6 %, p = 0.009) and more often 
a TIMI grade flow < 3 post PPCI (40.0 vs 8.2 %, p < 0.001), 
as displayed in supplemental Table 1.
Atrial fibrillation on day of admission
Mortality in patients in whom AF was detected on the day of 
admission was significantly higher compared with patients 
who were AF-free (7.3 vs 2.2 %, p = 0.036), as displayed in 
Table 1. In univariate analysis, age (odds ratio (OR) 1.123, 
p < 0.001), smoking (OR 0.275, p = 0.023), diabetes (OR 
4.774, p = 0.001), hypertension (OR 2.514, p = 0.043), Killip 
class > 1 (OR 8.314, p < 0.001), previous myocardial infarc-
tion (OR 3.942, p = 0.010), systolic (OR 0.641, p < 0.001) and 
diastolic (OR 0.530, p < 0.001) blood pressure on admission, 
Table 1 Association between 30-day post-infarction mortality and 
atrial fibrillation
Mortality
AF free AF p-value
AF on the day of 
admission
17/789 (2.2 %) 3/41 (7.3 %) 0.036
AF 24–72 h after 
admission
11/771 (1.4 %) 2/14 (14.3 %) < 0.001
AF > 72 after 
admission
8/750 (1.1 %) 0/18 (0 %) > 0.999
Data are presented as absolute number with percentages. p-value 
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previous studies. Furthermore, many studies have reported 
the independent association between AF and short- and long-
term mortality in both the otherwise healthy population [21, 
22] and in STEMI patients [6, 12, 23]. Several factors may 
predispose to AF in the setting of STEMI. Peri-infarction 
AF has been associated with an increased left ventricu-
lar diastolic dysfunction and end-diastolic pressure, which 
may increase atrial stretch and atrial pressure [24, 25]. Fur-
thermore, atrial dysfunction, atrial ischaemia, pericarditis, 
congestive heart failure due to ischaemia and enhanced sym-
pathetic tone may also play an important role in the genesis 
of post-infarction AF [26–28]. Finally, a previous study has 
reported that an irregular ventricular rate decreases cardiac 
output and increased pulmonary capillary wedge pressure 
and right atrial pressure, independent of heart rate [29].
Previous studies
Of note, a study [23] comparing prognosis of AF before and 
after PPCI reported that only AF post-PPCI was associated 
with an increase in long-term mortality. However, several 
differences between the present study and this study are 
No multivariate analysis was performed for AF > 72 h after 
admission. The analysis is displayed in supplemental Table 2.
Discussion
The current study reports the temporal association between 
new-onset AF and 30-day post-infarction mortality. AF on 
the day of admission and AF 24–72 h after admission were 
significantly associated with 30-day post-infarction mortal-
ity. In contrast, patients in whom AF was detected > 72 h 
after admission did not show an increased post-infarction 
mortality.
Predictors of mortality
In previous studies, age, diabetes, hypertension, Killip class, 
previous myocardial infarction, blood pressure on admis-
sion, culprit vessel and TIMI grade flow have been asso-
ciated with short-term post-infarction mortality [17–20]. 
Furthermore, smoking was associated with reduced short-
term mortality [18]. The present study is in line with these 
Table 3 Odds ratio analysis for all-cause 30-day mortality in patients 
with AF detected > 24 h after admission
Univariate OR 95 % CI p-value
Age (per year) 1.111 1.048–1.177 < 0.001
Gender male 2.146 0.754–6.105 0.152
BMI 1.055 0.913–1.219 0.468
Current smoker 0.375 0.118–1.186 0.095
Diabetes 5.911 2.052–17.025 0.001
Hypertension 1.800 0.646–5.015 0.261
Hypercholesterolaemia 1.044 0.329–3.314 0.942
Killip class > 1 7.275 2.574–20.556 < 0.001
Previous MI 4.300 1.331–13.895 0.015
Previous PCI 0.792 0.103–6.117 0.823
Systolic BP (per 10 mmHg) 0.708 0.555–0.902 0.005
Diastolic BP (per 10 mmHg) 0.611 0.423–0.883 0.009
Tirofiban study medication 0.254 0.071–0.906 0.035
Culprit vessel LADa 4.317 1.194–15.606 0.026
Culprit vessel LCXa N/A
TIMI grade flow post PCI < 3 4.061 1.258–13.106 0.019
AF 24–72 h after admission 11.515 2.300–57.662 0.003
Zwolle risk score 1.564 1.345–1.818 < 0.001
Multivariate analysis
AF 24–72 h after admission 13.476 2.138–84.954 0.006
Zwolle risk score 1.548 1.311–1.828 < 0.001
P-value for odds ratio in the prediction of 30-day mortalit
AF atrial fibrillation, BMI body mass index, MI myocardial infarction, 
PCI percutaneous coronary intervention, BP blood pressure, TIMI 
thrombolysis in myocardial infarction, LAD left anterior descending 
artery, LCx left circumflex artery, OR odds ratio, CI confidence 
interval
aas compared with culprit vessel right coronary artery
Table 2 Odds ratio analysis for all-cause 30-day post-infarction mor-
tality
Univariate OR 95 % CI p-value
Age (per year) 1.123 1.065–1.184 < 0.001
Gender male 1.733 0.682–4.406 0.248
BMI 1.035 0.901–1.188 0.628
Current smoker 0.275 0.090–0.835 0.023
Diabetes 4.774 1.852–12.304 0.001
Hypertension 2.514 1.029–6.140 0.043
Hypercholesterolaemia 0.957 0.344–2.665 0.933
Killip class > 1 8.314 3.365–20.544 < 0.001
Previous MI 3.942 1.387–11.200 0.010
Previous PCI 0.584 0.077–4.428 0.603
Systolic BP (per 10 mmHg) 0.641 0.516–0.796 < 0.001
Diastolic BP (per 10 mmHg) 0.530 0.383–0.732 < 0.001
Tirofiban study medication 0.254 0.084–0.766 0.015
Culprit vessel LADa 3.061 1.080–8.677 0.035
Culprit vessel LCxa 0.856 0.099–7.413 0.887
TIMI grade flow post PCI < 3 7.444 2.939–18.856 < 0.001
AF on the day of admission 3.585 1.007–12.764 0.049
Zwolle risk score 1.638 1.416–1.894 < 0.001
Multivariate analysis
AF on the day of admission 3.537 0.739–16.927 0.114
Zwolle risk score 1.625 1.404–1.880 < 0.001
P-value for odds ratio in the prediction of 30-day mortality. 
AF atrial fibrillation, BMI body mass index, MI myocardial infarction, 
PCI percutaneous coronary intervention, BP blood pressure, TIMI 
thrombolysis in myocardial infarction, LAD left anterior descending 
artery, LCx left circumflex artery, OR odds ratio, CI confidence 
interval
aas compared with culprit vessel right coronary artery
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Conclusion
Post-infarction AF occurring during the first 72 h after 
admission for STEMI was an important risk factor for mor-
tality. In contrast, AF detected > 72 h after STEMI was not 
associated with 30-day mortality.
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